Volume 2, Issue 1 And Supplement (Winter 2021)
J Vessel Circ 2021, 2(1 And Supplement): 31-31 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Iranmanesh F, Shafiee K, Farzan A. Trapeutic Effect of Donepezil and Memantine on Vascular Dementia. J Vessel Circ 2021; 2 (1) :31-31
URL: http://jvessels.muq.ac.ir/article-1-114-en.html
URL: http://jvessels.muq.ac.ir/article-1-114-en.html
1- Professor of Neurology, Stroke Fellowship, Neurology Research Center, Kerman, Iran
2- Assistant Professor of Neurology, Neurology Research Center, Kerman, Iran
3- Neurologist, Neurology Research Center, Kerman, Iran
2- Assistant Professor of Neurology, Neurology Research Center, Kerman, Iran
3- Neurologist, Neurology Research Center, Kerman, Iran
Abstract: (793 Views)
Background and Aim: Vascular dementia is one of the most common form of dementia. There is no treatment available to cure vascular dementia or to alter clinical course. The aim of this study was to evaluate the effects of donepezil, memantine, rivastigmine and galantamine on mean flow velocity (MFV) and Mini-Mental State Examination (MMSE).
Materials and Methods: This double-blind clinical trial was conducted on 44 patients with vascular dementia. Vascular dementia was diagnosed based on the DSM-V criteria. According to the order of entry into the study, the participants were treated with one of the drugs (donepezil (10 mg/d), memantine 10 mg/d ), galantamine (8 mg/d) and rivastigmine6 mg/d . The sampling finished whenever 11 patients in each group completed the three-month trial. The MMSE and color Doppler ultrasound was performed for all participants before and three months after the intervention.
Results: Our findings showed that memantine and donepezil significantly increased MMSE score (P = 0.009 and P = 0.001 respectively). Since there was no significant difference between the groups in the frequency of variables and the mean MMSE scores before the intervention, the administration of memantine and donepezil increased the MMSE scores. The findings also demonstrated that rivastigmine, galantamin and donepezil significantly increased MFV in some arteries.
Conclusion: Memantine and donepazil improve cognitive function in patients with vascular dementia. Rivastigmine, galantamin and donepezil increase MFV in some arteries although this effect seems limited.
Materials and Methods: This double-blind clinical trial was conducted on 44 patients with vascular dementia. Vascular dementia was diagnosed based on the DSM-V criteria. According to the order of entry into the study, the participants were treated with one of the drugs (donepezil (10 mg/d), memantine 10 mg/d ), galantamine (8 mg/d) and rivastigmine6 mg/d . The sampling finished whenever 11 patients in each group completed the three-month trial. The MMSE and color Doppler ultrasound was performed for all participants before and three months after the intervention.
Results: Our findings showed that memantine and donepezil significantly increased MMSE score (P = 0.009 and P = 0.001 respectively). Since there was no significant difference between the groups in the frequency of variables and the mean MMSE scores before the intervention, the administration of memantine and donepezil increased the MMSE scores. The findings also demonstrated that rivastigmine, galantamin and donepezil significantly increased MFV in some arteries.
Conclusion: Memantine and donepazil improve cognitive function in patients with vascular dementia. Rivastigmine, galantamin and donepezil increase MFV in some arteries although this effect seems limited.
Type of Study: Research |
Subject:
stroke
Received: 2021/08/1 | Accepted: 2021/02/28 | Published: 2021/02/28
Received: 2021/08/1 | Accepted: 2021/02/28 | Published: 2021/02/28
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Owned by Qom University of Medical Sciences
Published by Qom University of Medical Sciences Press
eISSN: 2717-0357
Email: jvessels[at]muq.ac.ir
j.vessels.circul[at]gmail.com
